Related Experiment Video
Updated: May 25, 2026
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
[Anti-myostatin antibody therapy for myopathies]
1Department of Neurology, Kawasaki Medical School.
Abstract:
Myostatin, a member of the muscle-specific transforming growth factor (TGF)-β family, negatively regulates skeletal muscle growth. It inhibits muscle stem cell proliferation and differentiation, and attenuates adult muscle fiber protein accretion, resulting in decreased skeletal muscle mass. Thus it has been considered to be a therapeutic target of myopathies including muscular dystrophy. Notably, administration of a blocking antibody against myostatin ameliorated the pathophysiology of dystrophin-deficient mdx mice. Although a clinical trial of an anti-myostatin antibody MYO-029 failed to achieve a significant outcome in patients with muscular dystrophies, various distinct approaches have been taken to establish anti-myostatin therapy including a myostatin decoy receptor ACE-031, a peptide drug derived from myostatin prodomain, small-molecule inhibitors against the myostatin receptor, a follistatin-derived peptibody inhibiting myostatin and myostatin siRNA with collagen-derived carrier particles. Clinical application of the anti-myostatin therapeutics for the treatment of patients with muscular dystrophy needs further evaluation of safety and specification of the target disease types among various muscular dystrophies.
Insights
Myostatin negatively regulates muscle growth and is a therapeutic target for myopathies. Various anti-myostatin therapies are being developed, but require further safety and efficacy evaluation for muscular dystrophy treatment.
Area of Science:
- Biochemistry
- Molecular Biology
- Muscle Physiology
Background:
- Myostatin, a TGF-β family member, inhibits skeletal muscle growth by suppressing muscle stem cell activity and protein accretion.
- Reduced skeletal muscle mass due to myostatin activity makes it a potential therapeutic target for myopathies like muscular dystrophy.
Purpose of the Study:
- To review the role of myostatin in skeletal muscle regulation.
- To explore various therapeutic strategies targeting myostatin for treating muscle-wasting disorders.
- To discuss the current status and future directions for anti-myostatin therapies.
Main Methods:
- Review of existing literature on myostatin function and therapeutic development.
- Analysis of preclinical data from animal models (e.g., mdx mice).
- Evaluation of clinical trial outcomes and emerging therapeutic modalities.
Main Results:
- Myostatin inhibition showed promise in preclinical models of muscular dystrophy.
- Clinical trials of anti-myostatin antibodies have yielded mixed results, with one notable failure (MYO-029).
- Diverse anti-myostatin approaches are under investigation, including decoy receptors, peptide drugs, small-molecule inhibitors, and gene-based therapies.
Conclusions:
- Myostatin remains a significant therapeutic target for muscular dystrophies and other myopathies.
- Further research is essential to optimize safety and efficacy of anti-myostatin treatments.
- Identifying specific muscular dystrophy subtypes responsive to these therapies is crucial for clinical application.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:21Satellite Stem Cells and Muscular Dystrophy
01:22Myasthenia Gravis ll: Pathophysiology
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...